For the quarter ending 2025-09-30, LPTX had -$8,444K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -3,303 | -32,078 |
| Non-cash operating lease expense | 0 | 224 |
| Stock-based compensation expense | 303 | 2,693 |
| Foreign currency transaction (gain) loss | 8 | -6 |
| Prepaid expenses and other assets | -704 | -67 |
| Accounts payable and accrued expenses | -6,267 | 596 |
| Research and development incentive receivable | - | 59 |
| Income tax payable | 195 | -227 |
| Lease liability | -1 | -227 |
| Other assets | -1 | -39 |
| Net cash used in operating activities | -8,317 | -28,966 |
| Proceeds from the exercise of stock options | 0 | 16 |
| Principal payments of insurance financing | 121 | 196 |
| Net cash provided by (used in) financing activities | -121 | -180 |
| Effect of exchange rate changes on cash and cash equivalents | -6 | 27 |
| Net decrease in cash and cash equivalents | -8,444 | -29,119 |
| Cash and cash equivalents at beginning of period | 47,249 | - |
| Cash and cash equivalents at end of period | 9,686 | - |
LEAP THERAPEUTICS, INC. (LPTX)
LEAP THERAPEUTICS, INC. (LPTX)